Nonalcoholic Fatty Liver Disease: Its Mechanisms and Complications
1Department of Physiology, University of Lausanne, Rue du Bugnon 7, 1005 Lausanne, Switzerland
2Départment Endocrinologie Metabolisme et Cancer, Institut Cochin, INSERM, U567, 22 Rue Méchain, 75014 Paris, France
3KineMed Inc., 5980 Horton Street, Emeryville, CA 94608, USA
4Biozentrum, University of Basel, Klingelbergstraße 70, 4056 Basel, Switzerland
5Section of Islet Cell and Regenerative Medicine, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215, USA
6Center for Integrative Genomics, University of Lausanne, Genopode, 1010 Lausanne, Switzerland
Nonalcoholic Fatty Liver Disease: Its Mechanisms and Complications
Description
Nonalcoholic fatty liver disease (NAFLD) is a hall mark of metabolic syndromes. The disease progresses from a simple fat accumulation (hepatic steatosis) to liver inflammation (nonalcoholic steatohepatitis, called NASH) and to liver cirrhosis. The prevalence of NAFLD in general population is around 20%, and it increases up to 90% in the obese population. Because of the concomitant metabolic disorders such as obesity and diabetes in NAFLD patients, the mechanisms by which the hepatic steatosis induces insulin resistance and NASH have still been unclear.
We invite investigators to contribute original research articles as well as review articles that will contribute to uncover mechanisms of how the liver deals with metabolic stress and develops hepatic steatosis and NASH. We encourage researchers to submit papers describing molecular pathologies underlying insulin resistance during NAFLD, clinical significance in NAFLD patients, and possible diagnosis and treatment against NAFLD.
We are particularly interested in articles describing new molecular pathways leading insulin resistance and/or inflammation in the liver, advances in molecular genetics and molecular diagnostics using animal models and siRNA techniques, evaluations of outcomes from treatment trials, new insight into cirrhosis development, and viral and nonviral gene therapy strategies. Potential topics include, but not limited to:
- Recent advances in understanding insulin resistance in NAFLD
- Role of inflammation in the development of NAFLD
- Role of hepatitis C virus in the development of NAFLD
- Recent advances in NAFLD treatment
- Population study and clinical trials in NAFLD
- Recent advances in drug discovery for NAFLD
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ije/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/ije/nafld/ according to the following timetable: